全國服務(wù)咨詢熱線：
18438616290
<b id="grzca"><menuitem id="grzca"></menuitem></b>
18438616290
簡要描述：Tranilast 53902-12-8Tranilast is an antiallergic drug by inhibiting lipid mediator and cytokine release from inflammatory cells, used for the treatment of allergic disorders such as asthma,
產(chǎn)品型號：abs47028131廠商性質(zhì)：生產(chǎn)廠家更新時間：2026-01-19訪 問 量：597產(chǎn)品分類
Product Category詳細(xì)介紹
| 品牌 | absin | CAS | 53902-12-8 |
|---|---|---|---|
| 分子式 | C18H17NO5 | 純度 | 99% |
| 分子量 | 327.33 | 貨號 | abs47028131 |
| 規(guī)格 | 10mg | 供貨周期 | 現(xiàn)貨 |
| 主要用途 | used for the treatment of allergic diso | 應(yīng)用領(lǐng)域 | 化工,生物產(chǎn)業(yè),農(nóng)林牧漁,制藥/生物制藥,綜合 |
Tranilast 53902-12-8
| 產(chǎn)品描述 | |
| 描述 | Tranilast is an antiallergic drug by inhibiting lipid mediator and cytokine release from inflammatory cells, used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. |
| 純度 | 99% |
| 儲存/保存方法 | Store at -20℃ for one year（Powder）；Store at 2-4℃ for two weeks；Store at -20℃ for six months after dissolution. |
| 基本信息 | |
| 別名 | 曲尼si特；MK 341；SB 252218 |
| 外觀 | 淡黃色或淡黃綠色結(jié)晶性粉末 |
| 可溶性/溶解性 | DMSO : 32.7 mg/mL (100 mM) |
| 生物活性 | |
| 靶點 | Angiotensin Receptor |
| In vitro(體外研究) | Tranilast is an anti-allergic drug inhibiting the release of substances such as histamine and prostaglandins from mast cells, which suppresses collagen synthesis of fibroblasts derived from keloid tissues. Tranilast (3-300 mM) suppresses the collagen synthesis of fibroblasts from keloid and hypertrophic scar tissue but not healthy skin fibroblasts. Tranilast (30-300 mM) inhibits the release of transforming growth factor (TGF)-beta 1 from keloid fibroblasts, which enhances the collagen synthesis of keloid fibroblasts. Tranilast improves keloids and hypertrophic scars which originate from the abnormal proliferation and excessive collagen accumulation of fibroblasts. Tranilast inhibits the release of TGF-beta 1, IL-1 beta and PGE2 from the human monocytes-macrophages. Tranilast inhibits the proliferation stimulated with fetal bovine serum (FBS), TGF-beta 1 and platelet-derived growth factor-BB (PDGF-BB) as well as PDGF-BB-induced migration. Tranilast exhibits inhibitory effects on spontaneous collagen synthesis and TGF-beta 1-induced collagen and glycosaminoglycan synthesis. |
| In vivo(體內(nèi)研究) | Tranilast results in a 58% reduction in TGF-beta1-induced 3-hydroxyproline incorporation in the diabetic heart of rats. Tranilast attenuates cardiac fibrosis by 37% in association with reduction in phospho-Smad2 in the diabetic heart of rats. Tranilast treatment completely prevents the increase in chymaselike activity, reduces the chymase mRNA levels by 43%, and decreases the carotid intima/media ratio by 63% in the carotid artery of dogs. |
| 參考文獻(xiàn) | |
| 參考文獻(xiàn) |
| 研究領(lǐng)域 | |
| 研究領(lǐng)域 | CancerCancer MetabolismCellular metabolic process CancerCancer MetabolismMetabolic signaling pathwayMetabolism of lipids and lipoproteins CardiovascularBloodBlood Pressure regulation CardiovascularBloodSerum Proteins CardiovascularVasculatureVasoconstrictionOther MetabolismPathways and ProcessesMetabolic signaling pathwaysLipid and lipoprotein metabolismLipid metabolism Drug DiscoverySmall Molecule DrugLead Compound Discovery |
產(chǎn)品咨詢
地址：上海市浦東新區(qū)新浩路58號申江科創(chuàng)園18棟
郵箱：
傳真：